HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
TUESDAY, May 23, 2017 (HealthDay News) -- For patients with relapsing-remitting multiple sclerosis (MS), natalizumab treatment is associated with enhancement of atypical lymphocytes, especially binucleated and plasmacytoid lymphocytes, according to a study published online May 8 in the International Journal of Laboratory Hematology.
Christoph Robier, M.D., from the Hospital of the Brothers of St. John of God in Graz, Austria, and colleagues compared eight defined morphological lymphocyte subtypes in peripheral blood smears in patients with relapse-remitting MS. Participants included 14 natalizumab-treated, 13 interferon-treated, and 10 untreated subjects.
The researchers found that compared with the interferon-treated and control groups, natalizumab-treated patients had significantly enhanced atypical lymphocytes (P < 0.0001). Only the natalizumab-treated group had binucleated lymphocytes (P = 0.0058 [versus interferon] and P = 0.018 [versus controls]), and plasmacytoid lymphocytes were more often found in the natalizumab group (both P < 0.0001).
"Knowledge of these natalizumab-associated changes in lymphocyte morphology may be relevant in clinical routine, to avoid unnecessary diagnostic procedures or even a discontinuation of natalizumab treatment," the authors write.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Updated on May 29, 2022